In alignment with the guidelines for the program, 31.365 treasury shares have been sold to employees of the Company.  The shares were acquired for NOK 22.5037 per share and are traded for NOK 19.128. This is a 15% discount on the acquisition price. The shares have a one-year lock-up period before they can be traded.

Following completion of the sale, the Company holds 0 own shares.

Certain primary insiders have participated in the program and have acquired a total of 6.600 shares. The number of shares purchased by each primary insider, together with their new total shareholding following the transaction, is as follows:

• Michael Akoh acquires 1.100 shares and will hold 8.760 shares in total.
• Børge Sørvoll acquires 1.100 shares and will hold 101.528 shares in total.
• Olav Lanes acquires 1.100 shares and will hold 8.100 shares in total.
• Marit Sjo Lorentzen acquires 1.100 shares and will hold 29.831 shares in total.
• Grethe Ytterstad acquires 1.100 shares and will hold 8.369 shares in total.
• Lill Hege Henriksen acquires 1.100 share and will hold 4.188 shares in total.

This information is made public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

About ArcticZymes Technologies ASA

Headquartered in Tromsø, Norway, ArcticZymes Technologies ASA is a publicly listed, leading provider of novel and high-quality enzymes for use in molecular research, diagnostics, and biomanufacturing. With over 30 years of expertise, the company develops and manufactures salt-active nucleases and other specialty enzymes inspired by the Arctic environment, enabling robust performance under demanding process conditions. ArcticZymes is certified to ISO 13485 and manufactures under relevant ICH GMP standards. 
For more information, visit www.arcticzymes.com.